Citation

Voelker J, Sheehan JJ, Le HH, Toro-Diaz H, Li S, Joshi K. J. Comp. Eff. Res. 2022; 11(5): 319-328.

Copyright

(Copyright © 2022, Future Medicine)

DOI

10.2217/cer-2021-0226

PMID

35073728

Abstract

BACKGROUND: Esketamine nasal spray plus an oral antidepressant is approved in adults with major depressive disorder with acute suicidal ideation or behavior (MDSI).

METHODS: A budget impact analysis from a US payer perspective was performed with a hypothetical 1-million-member plan, using pharmacy and medical costs associated with adding esketamine plus an oral antidepressant to usual care.

RESULTS: Estimated annual total healthcare costs of managing patients with MDSI increased from $32,988,247 without esketamine to $34,161,188 in Year 3 with esketamine (primarily due to medical costs). The per-member-per-month incremental costs were $0.02, $0.06 and $0.10 in Years 1, 2 and 3, respectively.

CONCLUSION: Incorporation of esketamine results in a modest estimated impact on the annual budget over a 3-year time horizon.

Language: en

Keywords

Humans; Adult; Suicidal Ideation; major depressive disorder; antidepressant; Ketamine; Health Care Costs; Depressive Disorder, Major; esketamine; Administration, Intranasal; budget impact; nasal spray; Nasal Sprays